InvestorsHub Logo

Rob777

09/21/21 10:11 AM

#355017 RE: sstyles #355013

That is a good commercial. Wish I would found
Out about it earlier $25 bucks a month is not bad is it prevents stomach issues and is better absorbed But let's see if all people care about is cost. Might be hard to sell next to a $2 bottle.

"
Those hopes have lifted PLX’s (ticker: PLXP) stock fivefold in the past year to a recent $17, and grown the Sparta, N.J.-based firm’s market capitalization from microscopic to about $500 million. Further gains from here will require PLX to make good on its ambition to convince millions of patients that Vazalore is worth $25 a month, instead of a couple of bucks for coated aspirin. It’s an intriguing bet—and one that an investor can handicap simply by scanning the shelves of her neighborhood retail chains."

lizzy241

09/21/21 11:03 AM

#355020 RE: sstyles #355013

sstyles, did you know that our very own Dr. Deepak Bhatt is on the board of PLXP=Vazalore? A business acquaintance of mine mentioned PLXP a few moons ago.
So why can't Vascepa create a commercial like Vazalore?

ggwpq

09/21/21 3:53 PM

#355045 RE: sstyles #355013

No mention of side effects. That's a great DTC ad.